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Background: Treatment of acute myeloid leukemia (AML) is widely centralized. Longer
distances to a specialized treatment center may affect patients’ access to curative-intended
treatment. Especially during outpatient treatment, distance may also affect survival.
Methods and patients: The authors conducted a national population-based cohort study
including all AML patients diagnosed in Denmark between 2000 and 2014. We investigated
effects of distance (<10 kilometers [km; reference], 10–25, 25–50, 50–100, >100) to the
nearest specialized treatment facility on the probability of receiving intensive chemotherapy,
HSCT, and achieving a complete remission (CR) using logistic regression analysis (odds
ratios; ORs). For overall survival, we used Cox proportional hazards regression (hazard
ratios [HRs]) and adjusted (a) for relevant baseline characteristics.
Results: Of 2,992 patients (median age=68.5 years), 53% received intensive chemotherapy
and 12% received low-dose chemotherapy outpatient regimens. The median distance to a
specialized treatment center was 40 km (interquartile range=10–77 km). No impact of
distance to specialized treatment centers was seen on the probability of receiving intensive
chemotherapy (10–25 km, aOR=1.1 (CI=0.7–1.7), 25–50 km, aOR=1.1 (CI=0.7–1.7), 50–
100 km, aOR=1.3 (CI=0.9–1.9), and >100 km, aOR=1.4 [CI=0.9–2.2]). Overall survival in
patients regardless of therapy (<10 km, aOR=1.0 vs >100 km, aOR=1.0 [CI=0.9–1.2]), in
intensive therapy patients, or in patients’ choice of post-remission was not affected by
distance to specialized treatment center. Distance to a transplant center also did not affect
the probability of HSCT or survival post-HSCT.
Conclusion: In Denmark, distance to a specialized treatment facility offering remission-
induction chemotherapy and HSCT does not negatively affect access to curative-indented
therapy, treatment-response, or survival in AML patients.
Keywords: hematology, allogeneic transplantation, socioeconomics, prognosis, epidemiology
Introduction
Acute myeloid leukemia (AML) is the most common form of acute leukemia in
adults. Treatment strategies range from supportive care, over low-dose chemother-
apy to high-dose intensive combination chemotherapy, potentially followed by
allogeneic stem cell transplantation (HSCT).1 Given the low incidence of only
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5,4/100.000 persons-years,2 the disease heterogeneity,3
broad spectrum of patients,4,5 therapeutic modalities, and
treatment-related complications, treatment often requires
referral to a specialized center. Several studies have
shown that patients referred to high-volume centers and
academic institutions have fewer treatment-related compli-
cations and better long-term outcomes for surgically trea-
ted cancers and also hematological cancers than patients
treated at low-volume and non-academic centers.6–8
To improve clinical decision-making and outcome, treat-
ment and care of AML patients especially intended for
remission-induction therapy and HSCT has, therefore, in
Denmark, been centralized at university hospitals.9,10
However, centralized treatment at specialized centers poten-
tially increases the median distance between the patient and
nearest treatment center and may affect access to treatment,
including allocation to remission-induction chemotherapy
and post-remission HSCTs. In addition, prompt initiation
of supportive care in cases of treatment-related complica-
tions may be delayed or limited in patients living furthest
away, ultimately affecting outcomes.
A recent review on the effects of distance to treatment
center on health outcomes (defined as survival, length of
stay, and non-attendance at follow-up) in different, mostly
non-acute patient categories, reported that 77% of studies
found an association between increasing distance and tra-
vel time to treatment center and worse health outcomes.11
However, only half of the studies included cancer patients,
and only one included HSCT patients. We believe that
AML patients differ from those included in these studies
in terms of acute presentation and the intensive regimens
increasing the risk of life-threatening complications.
As such, two previous studies investigated the impact of
distance to treatment center in AML patients and found no
effect on survival.12,13 Limitations included lack of indivi-
dual-level socioeconomic-, cytogenetic-, and treatment
information, as well as small and selected populations.
Although distance to a specialized treatment center
may affect access to treatment and survival in AML
more than in chronic diseases and solid cancers, the
Danish Healthcare setting may counteract these effects.
Denmark is a small country covering only 43,098 square
kilometers. It offers universal healthcare, thus patients
have full access to free diagnostic workup, treatment,
and follow-up within the public hospital system.2 Also,
transportation to outpatient visits during periods of mye-
losuppression and convenient hospital-covered housing for
patients and in some cases a relative at ”patient hotels”
specially designed for individuals with diseases and dis-
abilities are available during active treatment. No cancer
treatment takes place in Danish private hospitals, and
patients are referred to hospitals based on geography.
Though patients are free to choose another facility, almost
all patients are treated at the assigned and nearest specia-
lized treatment center.9,14
To investigate the impact of distance to the nearest
treatment center on outcome in AML in a universal health-
care setting, we conducted a nationwide populations-based
cohort study using individual-level clinical and socioeco-
nomic data, and estimated the effects of distance to the
nearest university hospital treating patients with intensive-
chemotherapy on the probability of remission-induction
chemotherapy, clinical trial inclusion, treatment response,
and overall survival in all Danish AML patients. Second,
we estimated the effect of distance to transplant center on
the probability of HSCT and overall survival post-
transplant.
Methods
In the universal healthcare context, we hypothesized that
the overall impact of distance would be negligible.
However, if any subgroup effect were to be more pro-
nounced, it would be expected to be during the outpatient
course.
The study population included all adult Danish AML
patients over the age of 25 years diagnosed between 2000
and 2014 registered in the Danish National Acute
Leukemia Registry (DNLR) (coverage >99%).2 We used
the Civil Person Registration (CPR) number assigned to all
Danish citizens at birth or immigration to link data from
different registries on an individual level (Figure 1A).15
Patient selection is shown in Figure 1B.
Treatment of AML
Remission-induction therapy and post-remission therapy are
centralized at five (six since 2013) specialized treatment
centers across Denmark, whereas only two centers are
accredited to perform HSCT (Rigshospitalet, Copenhagen
and, since 2009, Aarhus University Hospital).9 A national
board generates consensus recommendations for treatment
of AML, including recommendations for HSCT in CR1 and
in the relapse setting.16 No differences in treatment effects
across centers have yet been reported after adjusting for
unequal distribution of, e.g., age, sex, and cytogenetic
features, reducing the incentive to choose another treatment
center.17
Tøstesen et al Dovepress
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In AML, the only option to achieve a long-term survival is
by remission-induction intensive chemotherapy. Post-remis-
sion therapy consisted of one or two courses of consolidation
therapy, which was mostly administered in the inpatient set-
ting. However, patients were discharged immediately there-
after, unless complications occurred, followed by close
outpatient monitoring and support 1–3 times weekly between
chemotherapy cycles. In high-risk cases of AML, HSCT (fol-
lowing 1–2 cycles of consolidation chemotherapy) may be
recommended in CR1. Following HSCT in CR1, patients
undergoing myeloablative transplantation were managed in
the inpatient setting until engraftment, whereas reduced-inten-
sity conditioning patients living closer than 30 minutes from
the transplant center were managed as outpatients with daily
outpatient visits until neutrophil count >0.5 109/L. In HSCT
cases following non-ablative conditioning regimens, patients
were followed by 3 weekly visits until day 28 and by 1–2
weekly visits thereafter.
Due to high treatment-toxicity and increasing treatment
refractory disease in older patients, treatment options in older
and fragile patients are the non-curative treatment options;
including supportive care only and low-dose chemotherapy,
which may control the leukemia for shorter periods of time.
During the study period, patients receiving non-curative treat-
ment options could be followed at regional hematological
departments if they were closer to home.18
Socioeconomic information
Individualized socioeconomic information and demographics
were retrieved from registries at Statistics Denmark.19–23
The distance from the city center of habitation to the
nearest specialized treatment center offering remission-
induction therapy was calculated using the shortest route
(Google Maps) and grouped according to quintiles (<10,
10–25, 25–50, 50–100, >100 kilometers (km)). The dis-
tance to HSCT transplant center was grouped based on
quartiles (<10, 10–50, 50–200, >200 km).
Additional information included highest attained educa-
tion (primary education, secondary/vocational education,
and higher education), household income (tertiles), occupa-
tion (employed, unemployed, receiving disability or antici-
patory pension, and retirement pension), cohabitation (living
alone or with an adult partner), marital status (married
[including same-sex marriage], never married, divorced,
widowed),24,25 and Western/non-Western origin. Western
origin was defined as persons born outside of Denmark in a
EU country, Andorra, Iceland, Liechtenstein, Monaco,
Norway, San Marino, Switzerland, Vatican City, Canada,
the US, Australia, or New Zealand.23
Clinical data
We obtained baseline demographics, laboratory results, and
treatment information from the DNLR.2 Cytogenetic results
were grouped according to MRC’s criteria (favorable, inter-
mediate, adverse).26 Type of AMLwas grouped into de novo,
secondary [s-AML], and therapy-related AML [t-AML].4
Information on non-AML-related comorbidities (according
to a modified version of the Charlson Comorbidity Index,5
and cumulative length of hospital admission (day 0–100)
were retrieved from The Danish National Patient Registry.
Information regarding HSCT (e.g., date and disease stage)
was obtained from local registries.
Outcomes
Primary outcomes were treatment with remission-induction
chemotherapy, probability of CR defined as morphological
CR after up to two cycles of induction therapy,27 HSCT
performance in first complete remission (CR1), and overall
survival. Remission-induction regimens was defined as stan-
dard to high-dose of cytarabine (≥100–400 mg/m) in combi-
nation with an anthracycline or anthracycline-like
compound.28 Low-dose chemotherapy was defined as hypo-
methylating agents, low-dose cytarabine, or similar.
Supportive care was defined as the absence of chemotherapy
(hydroxyurea excluded) and included, e.g., blood products
and antibiotics. Information on each patient’s vital status was
obtained from the Civil Registration System. Secondary out-
comes were pre-specified and included time from diagnosis
to initiation of remission-induction therapy, cumulative
length of hospital admission (day 0–100; from the DNLR)
as a surrogate for complications during the induction phase.
Statistical analyses
We stratified descriptive data by distance to the nearest
specialized treatment center.
We used logistic regression analysis to estimate the
probability of remission-induction therapy by distance to
a specialized treatment center in all patients, the probabil-
ity of consolidating HSCT in first complete remission
(CR1) for transplantation candidates (age<70 years,
achievement of CR, non-favorable cytogenetics),16 and
the probability of CR in patients receiving remission-
induction therapy (crude and adjusted odds ratios [ORs]).
Patients were followed from diagnosis until death,
emigration, or end of follow-up (February 18, 2016). We
Tøstesen et al Dovepress
submit your manuscript | www.dovepress.com
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Table 1 Patient characteristics according to distance to nearest specialized treatment center in 2,992 adult AML patients
Distance to nearest specialized treatment center
<10 km 10–25 km 25–50 km 50–100 km >100 km
n=726 (24.6%) n=435 (14.5%) n=612 (20.5%) n=700 (23.4%) n=519 (17.3%)
Patient characteristics, n
Sex, men (%) 380 (52,34) 247 (56.78) 343 (56.05) 399 (57.00) 283 (54.53)
Age, years, median (IQR) 69 (56–77) 68 (58–76) 69 (58–77) 68 (59–76) 68 (59–76)
Non-Western origin, n (%) ≤5 (≤1.0)) 11 (1.6) 8 (1.3) 12 (2.8) 26 (3.6)
Socioeconomic indicators, n (%)
Income
Low (1st third) 205 (28.24) 120 (27.59) 210 (34.31) 254 (36.29) 209 (40.27)
Medium–low (2nd third) 233 (32.09) 145 (33.33) 212 (34.64) 236 (33.71) 171 (32.95)
High (3rd third) 288 (39.67) 170 (39.08) 190 (31.05) 210 (30.00) 139 (26.78)
Employment
Employed/self-employed 240 (33.06) 156 (35.86) 174 (28.43) 216 (30.86) 176 (33.91)
Unemployed/ leave 20 (2.75) 11 (2.53) 20 (3.27) 17 (2.43) 12 (2,31)
Anticipatory pension 90 (12,40) 53 (12.18) 86 (14.05) 96 (13.71) 69 (13.29)
Retirement pension 376 (51.79) 215 (49.43) 332 (54.25) 371 (53.00) 262 (50.48)
Education
Short 264 (36,36) 168 (38.62) 282 (46.08) 357 (51.00) 265 (51.06)
Medium 280 (38.57) 190 (43.68) 237 (38.73) 252 (36.00) 179 (34.49)
Longer 182 (25.07) 77 (17.70) 93 (15.20) 91 (13.00) 75 (14.45)
Cohabitation status
Living with someone 398 (54.82) 292 (67.13) 419 (68.46) 486 (69.43) 363 (69.94)
Living alone 328 (45.18) 143 (32.87) 193 (31.54) 214 (30.57) 156 (30.06)
Disease and treatment characteristics
Admission time (day 0–100), median (IQR) 41 (31–53) 36 (24–51) 42 (29–55) 45 (30–58) 47 (34–61)
Time to therapy, days, median (IQR) 3 (1–7) 4 (1–8) 3 (1–7) 4 (1–9) 4 (1–7)
Intent of treatment
Intensive treatment 374 (51.52) 234 (53.79) 319 (52.12) 379 (54.14) 282 (54.34)
Protocol participation, intensive therapy patients.
Yes 122 (32.62) 73 (31.20) 88 (27.59) 127 (33.51) 80 (28.37)
Comorbidities, scorea (%)
0 394 (59.07) 230 (57.64) 309 (57.12) 366 (56.74) 284 (59.17)
1 165 (24.74) 103 (25.81) 152 (28.10) 197 (30.54) 114 (23.75)
≥2a 108 (16.20) 66 (16.54) 80 (14.79) 82 (12.71) 82 (17.08)
WHO PS, n (%)
0 205 (28.55) 130 (30.30) 182 (29.89) 171 (24.50) 114 (21.97)
1 297 (41.36) 172 (40.09) 245 (40.23) 312 (40.70) 241 (46.44)
≥2 216 (30.08) 127 (29.60) 182 (29.89) 215 (30.80) 164 (31.60)
tAML, n (%) 43 (5.92) 38 (8.74) 49 (8.01) 53 (7.57) 30 (5.78)
sAML, n (%) 145 (19.97) 95 (21.84) 122 (19.93) 152 (21.71) 94 (18.11)
Blast count marrow, %, median (IQR) 50 (30–75) 50 (30–78) 50 (30–74) 53 (35–72) 50 (30–74)
Blast count blood, %, median (IQR) 24 (4–60) 25 (5–61) 24 (5.5–52) 22 (4–53) 20 (4–59)
(Continued)
Dovepress Tøstesen et al
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Table 1 (Continued).
Distance to nearest specialized treatment center
<10 km 10–25 km 25–50 km 50–100 km >100 km
n=726 (24.6%) n=435 (14.5%) n=612 (20.5%) n=700 (23.4%) n=519 (17.3%)
WBC, x109/L, median (IQR) 12.1 (2.5–54.8) 11.0 (2.4–47.3) 8.6 (2.2–42.9) 9.6 (2.2–45) 8.65 (2.3–43.5)
Platelet count, x109/L, median (IQR) 54 (27–104) 52 (30–103) 52 (27–100) 50 (25–96) 54 (28–110)
Extra-medullary AML, n (%) 54 (7.95) 40 (9.93) 53 (9.28) 58 (9.09) 42(9.09)
Cytogenetic risk group, MRC, n (%)
Favorable risk 21 (2.89) 18 (4.14) 17 (2.78) 25 (3.75) 17 (3.28)
Intermediate risk 394 (54.27) 206 (47.36) 337 (55.07) 399 (57.00) 293 (56.45)
Adverse risk 121 (16.67) 78 (17.93) 104 (16.99) 150 (21.43) 99 (19.08)
Karyotype, n (%)
Normal karyotype 237 (47.88) 129 (45.26) 209 (50.98) 252 (47.82) 192 (51.20)
Abnormal karyotype 258 (52.12) 156 (54.74) 201 (49.02) 275 (52.18) 183 (48.80)
Note: aAccording to the modified Charlson’s Comorbidity Index, which includes non-leukemia-related comorbidity.
Abbreviations: AML, acute myeloid leukemia; QR, interquartile range (25–75 centiles); HSCT, allogeneic stem cell transplantation; CR1, 1st complete remission; WHO PS,
World Health Organization Performance Status; tAML, therapy-related AML; sAML, secondary AML; WBC, white blood count; MRC, Medical Research Council.
Table 2 Association between distances to nearest specialized treatment center and probability of intensive chemotherapy in 2,992
acute myeloid leukemia patients. Logistic regression analysis, crude, and adjusted estimatesa
All patients Intensive chemotherapy, pts. (%) Odds ratio, crude (95% CI) Odds ratio, adjusted (95% CI)
Distance
<10 km 374 (51.5) 1.0 1.0
10–25 km 234 (53.7) 1.1 (0.9–1.4) 1.1 (0.7–1.7)
25–50 km 319 (52.1) 1.0 (0.8–1.3) 1.1 (0.7–1.7)
50–100 km 379 (54.1) 1.1 (0.9–1.4) 1.3 (0.9–2.0)
>100 km 282 (54.3) 1.1 (0.9–1.4) 1.4 (0.9–2.2)
Patients <65 years
Distance
<10 km 257 (89.2) 1.0 1.0
10–25 km 154 (89.5) 1.0 (0.6–1.9) 1.3 (0.5–3.3)
25–50 km 207 (88.5) 0.9 (0.5–1.6) 1.2 (0.5–2.8)
50–100 km 237 (89.8) 1.1 (0.6–1.8) 1.7 (0.7–4.1)
>100 km 187 (95.4) 2.5 (1.2–5.4) 7.5 (2.0–27.5)
Patients ≥65 years
Distance
<10 km 117 (26.7) 1.0 1.0
10–25 km 80 (30.4) 1.2 (0.9–1.7) 1.0 (0.6–1.8)
25–50 km 112 (29.6) 1.2 (0.9–1.6) 1.1 (0.7–1.9)
50–100 km 142 (32.6) 1.3 (1.0–1.8) 1.3 (0.8–2.1)
>100 km 95 (29.4) 1.1 (0.8–1.6) 1.0 (0.6–1.8)
Notes: aResults adjusted for age, sex, cohabitation, income, educational level, occupation, white blood cell count, cytogenetic risk group, WHO performance status, type of
leukemia (de novo, secondary or therapy-related AML) and comorbidity.
Abbreviations: AML, acute myeloid leukemia; 95% CI, 95% confidence interval.
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used Kaplan-Meier curves and Cox proportional hazards
regression (hazard ratios [HRs] to assess the impact of
distance to the nearest specialized treatment center on
overall survival in all patients and in remission-induction
therapy patients only. In addition, we estimated survival in
mainly outpatient patients; patients receiving low-dose
chemotherapy only, in patients post-remission (starting
follow-up at time of CR1), and in HSCT patients post-
transplant (starting follow-up at time of HSCT)). The
proportional hazards model assumptions were graphically
verified by log minus log plot and accepted.
Potential confounders were identified based on the
current literature and drawing and analyzing causal dia-
grams (DAGs). All results were given crude and adjusted
for the patient-related factors (sex, age [continuous], edu-
cation, income, occupation, cohabitation status, and
comorbidity [categorical]) as well as leukemia-related fac-
tors (white blood cell count [continuous], cytogenetics risk
group, type of AML, and WHO/EGOG performance status
[categorical]).29
We used shortest distance as reference. Estimates were
given with corresponding 95% confidence intervals (CIs).
To test the robustness of our results, we repeated analyses
using the distance to nearest specialized treatment center and
HSCTcenter as continuous variables and stratified bymedian
age (<65, ≥65 years) to address possible effect modification.
In HSCT patients, we repeated survival analysis starting
follow-up at day 100, to investigate survival effects in the
HSCT outpatient setting. Finally, we repeated the primary
analysis using a multiple imputation strategy, imputing miss-
ing values for possible confounders (WHO PS (0.5%), WBC
(3%), comorbidity (8%), and cytogenetic risk group (in
intensive therapy patients, 13%)).30–32
Statistical analyses were performed using Stata version
14.1 (Stata Corp., College Station, TX). The study was
approved by the Danish Data Protection Agency (jr.nr. 1–
16-02–321-18).
Results
Patient characteristics
A total of 2,992 patients diagnosed with AML were
included in the study (Figure 1A). The median age at
diagnosis was 68.5 years, and the median distance to a
specialized treatment center was 40 km (interquartile
range=10–77 km). Patients living furthest from a specia-
lized center had a lower income and lower educational
level. The median distance to a transplant center was 197
km (IQR=47–293).
Patient characteristics according to distance to nearest
specialized treatment center treating patients with inten-
sive chemotherapy are listed in Table 1. Patients originat-
ing from non-Western countries (≈2%) tended to live
further from a specialized treatment center than patients
of Western origin.
Effects of upfront AML treatment choice
Overall, 1,588 (53%) received intensive chemotherapy.
Table 2 shows the association between the distance to
the nearest specialized treatment center and the probability
of treatment with intensive chemotherapy.
Overall, distance to a specialized treatment center did
not affect the probability of receiving remission-induction
chemotherapy. However, patients younger than 65 years
living >100 km from a specialized treatment center had a
higher absolute probability of receiving intensive che-
motherapy compared with patients younger than 65 years
with a distance <10 km (95.4% vs 89.2%, aOR=7.5 (95%
CI=2.0–27.5).
Of the 1,404 patients treated with non-curative treat-
ment options, 24.7% (n=350) received low-dose outpatient
chemotherapy and the remaining supportive care only. The
proportion of patients receiving low-dose chemotherapy vs
supportive care-only did not vary by distance to a specia-
lized treatment center. In patients receiving low-dose che-
motherapy, crude and adjusted survival from time of
diagnosis was also not affected by distance to a specialized
treatment center (Figure 2).
Treatment response in intensive therapy
patients
Of the 1,588 patients receiving intensive chemotherapy,
71% (n=1,045) obtained a CR (75.9% in patients <65
years, 62.6% in patients ≥65 years). The proportion of
patients achieving CR did not vary by distance to a spe-
cialized treatment center. Crude and adjusted results are
shown in Table 3. No effect of distance to specialized
treatment center was observed on the probability of
achieving a CR after induction chemotherapy.
Probability of HSCT in CR1 and survival
from time of HSCT
In the 866 patients younger than 70 years with non-
favorable cytogenetic who achieved a CR1, 184 (21%)
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patients received an HSCT in CR1. Consolidation with a
HSCT was more common in patients living closest to a
transplant center (distance <10 km, 20.4%; 10–50 km,
17.8% (OR=0.8, CI=0.5–1.3), 50–200 km, 12.4%
(OR=0.6, CI=0.3–0.9); >200 km, 14.6% (OR=0.7,
CI=0.4–1.1)). However, adjustment for age and other
potential confounders weakened this association (10–50
km, aOR=0.9 (CI=0.5–1.5); 50–200 km, aOR=0.7 (0.4–
1.2); >200 km, aOR=0.8 (0.5–1.4) compared with dis-
tance <10 km). Restricting analysis to patients diagnosed
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Figure 2 Association between distances to the nearest specialized treatment center and mortality. Results of all AML patients by age and by treatment intensity. Cox
regression analysis, crude, and adjusted estimates.a
Notes: Patients followed from time of diagnosis to death or end of follow-up. aResults adjusted for age, sex, cohabitation, income, educational level, occupation, white blood
cell count, cytogenetic risk group, WHO performance status, type of leukemia (de novo, secondary, or therapy-related AML) and comorbidity.
Abbreviations: AML, acute myeloid leukemia; 95% CI, 95% confidence interval.
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Table 3 Association between distances to nearest specialized treatment center and probability of CR in 1,463 AML patients treated
with remission-induction therapy. Logistic regression analysis, crude, and adjusted estimatesa
All patients CR, patients (%) Odds ratio, crude (95% CI) Odds ratio, adjusted (95% CI)
Distance
<10 km 252 (73.0) 1.0 1.0
10–25 km 147 (68.4) 0.8 (0.5–1.2) 1.1 (0.8–1.6)
25–50 km 200 (68.7) 0.8 (0.6–1.1) 1.0 (0.7–1.4)
50–100 km 251 (71.9) 0.9 (0.7–1.3) 1.1 (0.8–1.6)
>100 km 195 (74.1) 1.1 (0.7–1.5) 1.3 (0.9–1.9)
Patients <65 years
Distance
<10 km 187 (77.0) 1.0 1.0
10–25 km 104 (71.2) 0.7 (0.5–1.2) 0.8 (0.42–1.33)
25–50 km 141 (72.7) 0.8 (0.5–1.2) 0.9 (0.49–1.45)
50–100 km 168 (77.8) 1.0 (0.7–1.6) 1.1 (0.65–1.88)
>100 km 139 (79.4) 1.2 (0.7–1.9) 1.2 (0.65–2.08)
Patients ≥65 years
Distance
<10 km 65 (63.7) 1.0 1.0
10–25 km 43 (62.3) 0.9 (0.5–1.8) 1.3 (0.6–2.7)
25–50 km 59 (60.8) 0.9 (0.5–1.6) 1.0 (0.5–1.9)
50–100 km 83 (62.4) 0.9 (0.6–1.6) 1.1 (0.6–2.0)
>100 km 56 (63.6) 1.0 (0.6–1.8) 0.9 (0.5–1.9)
Notes: aResults adjusted for age, sex, cohabitation, income, educational level, occupation, white blood cell count, cytogenetic risk group, WHO performance status, type of
leukemia (de novo, secondary or therapy-related AML) and comorbidity.
Abbreviations: AML, acute myeloid leukemia; 95% CI, 95% confidence interval; CR, complete remission.
Figure 3 Crude survival according to categorical distance to the nearest specialized treatment center. Overall survival in all patients (A), in patients <65 years (B), in all
patients ≥65 years (C), in all patients receiving intensive chemotherapy (D), and in all patients receiving intensive chemotherapy surviving to achieve a CR (E).
Abbreviations: AML, acute myeloid leukemia; CR, complete remission.
Dovepress Tøstesen et al
Clinical Epidemiology 2019:11 submit your manuscript | www.dovepress.com
DovePress
777
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
3.
13
1.
88
 o
n 
16
-O
ct
-2
01
9
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
before 2009 when HSCTs were exclusively performed at
Copenhagen University Hospital (Rigshospitalet) and the
distance, therefore, was extended for patients in the
Western half of Denmark, did not change the estimates.
In the patients receiving a HSCT in CR1, the distance
to a transplant center did not impact survival from time of
transplant (10–50 km, OR=0.9 (CI=0.5–1.8); 50–200 km,
OR=1.0 (0.4–2.3); >200 km, aOR=0.9 (0.4–1.8) compared
with distance <10 km). Starting follow-up at day 100 post-
transplant did not change the interpretation of results.
Overall survival in all patients, in intensive
therapy patients, and in CR patients only
The total time from diagnosis to the end of follow-up was
5,544 years. Among patients receiving intensive che-
motherapy, the follow-up time was 4,850 years and median
follow-up was 514.5 days (interquartile range=179.5–1451
days). Figure 2 shows crude survival by distance to a
specialized treatment center for patients overall, in inten-
sive therapy patients only, and by age.
Figure 3 shows crude and adjusted estimates (ORs) and
Forest plots according to categorical distance overall, by
age group, and by treatment intensity. For all patients,
irrespective of treatment intensity and age group, no dif-
ference in overall survival was observed between groups
of varying distance to treating hospital. Adjusting for
confounders did not change the interpretation of the
results. Also, no effect of distance to a specialized treat-
ment center was observed for intensive therapy patients
only. Once in remission following induction chemotherapy
(n=959), distance still had no impact on survival.
Sensitivity analyses
In general, stratifying analyses by age did not modify any
of the results (stratified by median age, <65 and ≥65
years). Analyzing the distance to the nearest treatment
center as a continuous variable did not change the inter-
pretation of the probability of CR (aOR=1.0; 95%
CI=0.99–1.0). Finally, imputing missing values for clinical
and socioeconomic factors did not affect results.
Discussion
In this large population-based study investigating the
effect of distance to a specialized treatment center, we
did not find increased distance to the treatment center to
negatively affect access to intensive chemotherapy or
HSCT, the probability of CR, or survival in AML patients
neither in the inpatient or outpatient settings when adjust-
ing for potential confounding factors.
In general, distance did not affect access to intensive
chemotherapy or HSCT. However, patients younger than
65 years traveling more than 100 km had a higher prob-
ability of receiving chemotherapy after adjusting for
available confounding factors. The precision of this esti-
mate was low, and this finding may well be explained by
chance. The absolute difference in the probability of
intensive chemotherapy was only 6% in a high-preva-
lence cohort, in which case odds ratios cannot be trans-
lated into relative risks and may appear inflated.33
Importantly, the findings of a higher probability of remis-
sion-induction chemotherapy did not translate into better
overall survival.
This study was based on high-quality registries includ-
ing the CPR-registry, which allowed us to obtain detailed,
complete, and up-to-date follow-up data reducing misclas-
sification bias. It was possible to obtain data on important
clinical factors, thereby allowing us to investigate a pos-
sible effect in several patient sub-groups and at different
times during the disease course. Also, detailed information
on important prognostic factors made it possible to take
most relevant confounders into account. Data was obtained
prospectively and unrelated to the study aim, thereby
reducing information bias. The median distance was com-
parable to prior studies both from the US (eg, a median of
24 miles [38 km] for remission-induction therapy and a
range of 2–358 minutes for HSCT).12,34
Few previous US studies found longer travel distance
to be associated with superior treatment outcomes in other
malignancies, likely explained by distance bias
associations.11 Differences in AML outcomes have been
shown between eg, academic centers and non-academic
centers in the US.35 Though under-insured and low-
income patients may live furthest from the nearest poten-
tial treatment center, well-insured and socioeconomically
prosperous with a priori superior prognosis may be moti-
vated and able to travel further to get treatment at the
leading academic institutions, which may bias results.
Interestingly, two US acute leukemia studies conducted
in completely different settings have previously found com-
parable results. Master et al.13 examined 67,443 AML
patients and found no survival difference between patients
living <30 vs >30 miles from the treatment center (HR for
OS=0.99; 95% CI=0.99–1.02),whereas Rodriguez et al.,12
in a single center study including only 281 intensive therapy
AML patients, found no correlation of OS with an increase
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in distance to treatment center by 20 mile intervals (HR for
OS=0.99; 95% CI=0.98–1.02). Though these studies imply
that distance, also in large countries with insurance-based
healthcare, does not affect treatment and outcomes in AML,
bias and important methodological limitations might
explain the results in selected cohorts of patients who are
able to make it to these treatment centers.
A lack of associations between effects of distance and
survival has also been reported inHSCTpatients.36 In contrast,
one study reported that distance to the HSCTcenter negatively
affected survival more than 1-year after HSCT,34 but patients
with severe complications eg, chronic graft vs host disease, not
being referred back to their local oncologist could explain the
lack of survival difference in the first year.
We found a clear association between distance >200
km to the HSCT center and a reduced probability of HSCT
performance. However, after confounder adjustment this
association was less clear and overall survival in intensive
therapy patients was not affected.
Our findings may be affected by the Danish universal
healthcare system. Still, it is likely that very long distances
may affect the probability of “prophylactic” procedures requir-
ing extensive follow-up for months and in the case of GVHD
for years. For the same reasons, it is likely that an eventual
survival effect of long distance to specialized treatment center
would especially affect patients in the outpatient setting, since
time and distance may negatively impact access to life-saving
procedures and close follow-up. However, we did not find
distance to have an effect on survival in these subgroups: low-
dose chemotherapy patients, intensive therapy patients in CR,
and also not in HSCT patients post-transplant.
We have recently shown that, though Denmark offers
universal healthcare, specifically socioeconomic factors do
affect access to treatment and survival in AML patients. In
contrast to distance to the specialized treatment center,
advanced age and living alone have been found to affect
Danish patients’ access to intensive chemotherapy and,
thus, overall survival.24 Also, education, but not income,
has an impact on the probability of undergoing a HSCT and
on overall survival in patients younger than 60 years.25 In
these patients, adjusting for distance to the treatment center
did not affect reported results.
Our study has limitations. We used the shortest distance
and not alternative measures of potential barriers to reach a
treatment center, such as travel time or costs. Denmark consists
of more than 400 islands, 70 of those populated, but most
connected by bridges.23 A small percentage of patients living
on islands requiring ferry transportation may experience a
significant geographical barrier not captured by this study.
Patients of non-Western origin tended to live further from a
specialized treatment center. Only accounting for 2%, not
adjusting for this is unlikely to influence the overall results.
Still, it would have been interesting to investigate a potential
subgroup effect in these patients. Our analyses did not account
for changes in location during the treatment cause, but almost
all patients are treated at the closest specialized treatment
center, and potential misclassification is thought to be non-
differential and neglectable.Despite the high completeness and
quality of individual variables, the limitations included the
exclusion of patients with missing data on treatment intent
(1.4%), education, cohabitation, and income (8.9%).
However, median distance and characteristics of these patients
did not differ from the final study population, and thus, it is not
likely to have affected the overall conclusions.
Conclusion
In a population-based setting, distance, to the specialized
treatment facility offering remission-induction chemother-
apy or HSCT, does not negatively affect access to care and
survival in AML patients. These findings support that the
current centralization of specialized treatment aiming to
treat AML at high-volume centers only does not negatively
affect AML outcomes in a universal healthcare system.
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